Optimizing CAR structures to enhance efficacy in solid tumours

𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
In this webinar, Dr. Marc Davies, VP of R&D at Leucid Bio, outlines how the optimisation of CAR structure can be used to enhance T-cell efficacy. The move from a traditional ‘linear’ configuration, in which signalling domains are placed in cis (and thus progressively further from the plasma membrane) to a ‘lateral’ structure, in which the signalling domains are placed across the plasma membrane (and thus at their endogenous membrane-proximal locations) enhances the proliferation, survival and anti-tumour activity of the CAR T-cells, resulting in substantial efficacy across multiple in vivo models of solid tumours. These lateral CAR T-cells can then be combined with appropriate armouring technologies to further enhance anti-tumour efficacy.

𝗦𝗽𝗲𝗮𝗸𝗲𝗿𝘀:
-Dr Marc Davies, VP of R&D at Leucid Bio
-Dr Stacie Chvatal, Director of Product Management at Axion BioSystems

𝗟𝗲𝗮𝗿𝗻𝗶𝗻𝗴 𝗢𝗯𝗷𝗲𝗰𝘁𝗶𝘃𝗲𝘀:
Current status of CAR T cell therapy for solid tumors
How to optimize CAR structure during immunotherapy development for enhanced efficacy
Using the Axion Omni FL and Omni Pro 12 live-cell imaging platform to evaluate potency of cell therapies in vitro

𝗥𝗲𝘀𝗼𝘂𝗿𝗰𝗲𝘀:
Explore Axion's Immuno-oncology applications: https://axionbiosystems.com/applicati...
Download Axion's Immuno-oncology development brochure: https://axionbiosystems.com/resources...
Omni Brochure: https://axionbiosystems.com/sites/def...